Effectiveness of Dipeptidyl Peptidase IV Inhibitors in the Management of Chronic Obstructive Pulmonary Disease: A Meta-Analysis
DOI:
https://doi.org/10.37275/bsm.v8i11.1110Keywords:
COPD, Dipeptidyl peptidase IV inhibitors, Exacerbations, Lung function, Meta-analysisAbstract
Background: Chronic obstructive pulmonary disease (COPD) is a major global health issue. Recent research suggests dipeptidyl peptidase IV (DPP-IV) inhibitors, primarily used in diabetes management, may have beneficial effects on lung function and inflammation in COPD. This meta-analysis aims to assess the efficacy and safety of DPP-IV inhibitors in COPD.
Methods: A systematic search of PubMed, Embase, and Cochrane Library databases was conducted from January 2018 to June 2024. Randomized controlled trials (RCTs) comparing DPP-IV inhibitors with placebo or standard COPD therapy in patients with COPD were included. Data on lung function (FEV1), quality of life, exacerbations, and adverse events were extracted. Meta-analyses were performed using random-effects models.
Results: Ten RCTs involving 4,520 patients were included. DPP-IV inhibitors were associated with a significant improvement in FEV1 compared to placebo or standard therapy (mean difference: 55 ml, 95% CI: 30-80 ml, p<0.001). Quality of life scores also showed a trend toward improvement. The rate of moderate-to-severe exacerbations was significantly lower in the DPP-IV group (risk ratio: 0.75, 95% CI: 0.60-0.93, p=0.008). Adverse events were similar between groups.
Conclusion: DPP-IV inhibitors may be a promising adjunctive therapy in COPD management, improving lung function, and quality of life, and reducing exacerbations. Further research is warranted to confirm these findings and investigate long-term effects.
Authors
- Joas Vinsensius Davian1*
- Zen Fadil Ahmad2
- Rouly Pola Pasaribu2
- 1Faculty of Medicine, Universitas Sriwijaya/Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia
- 2Division of Pulmonology, Department of Internal Medicine, Universitas Sriwijaya/Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia
Corresponding author Joas Vinsensius Davian — Dr.joasvdavian@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
